BlackRock’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-7,330,329
| Closed | -$82.1M | – | 5095 |
|
|
2017
Q3 | $82.1M | Buy |
7,330,329
+939
| +0% | +$10.4K | ﹤0.01% | 1959 |
|
|
2017
Q2 | $80.6M | Sell |
7,329,390
-245,334
| -3% | -$2.45M | ﹤0.01% | 1946 |
|
|
2017
Q1 | $74.2M | Buy |
7,574,724
+7,568,384
| +119,375% | +$75.6M | ﹤0.01% | 1973 |
|
|
2016
Q4 | $68K | Sell |
6,340
-1,223
| -16% | -$12.2K | ﹤0.01% | 2791 |
|
|
2016
Q3 | $78K | Buy |
7,563
+643
| +9% | +$7K | ﹤0.01% | 2742 |
|
|
2016
Q2 | $91K | Buy |
6,920
+2,586
| +60% | +$33.9K | ﹤0.01% | 2593 |
|
|
2016
Q1 | $48K | Buy |
4,334
+704
| +19% | +$6.26K | ﹤0.01% | 2385 |
|
|
2015
Q4 | $33K | Buy |
3,630
+1,800
| +98% | +$15.1K | ﹤0.01% | 2308 |
|
|
2015
Q3 | $13K | Hold |
1,830
| – | – | ﹤0.01% | 2626 |
|
|
2015
Q2 | $18K | Sell |
1,830
-400
| -18% | -$3.64K | ﹤0.01% | 2461 |
|
|
2015
Q1 | $20K | Hold |
2,230
| – | – | ﹤0.01% | 2378 |
|
|
2014
Q4 | $19K | Hold |
2,230
| – | – | ﹤0.01% | 2411 |
|
|
2014
Q3 | $16K | Hold |
2,230
| – | – | ﹤0.01% | 2470 |
|
|
2014
Q2 | $12K | Hold |
2,230
| – | – | ﹤0.01% | 2684 |
|
|
2014
Q1 | $10K | Hold |
2,230
| – | – | ﹤0.01% | 2746 |
|
|
2013
Q4 | $12K | Hold |
2,230
| – | – | ﹤0.01% | 2635 |
|
|
2013
Q3 | $12K | Hold |
2,230
| – | – | ﹤0.01% | 2556 |
|
|
2013
Q2 | $11K | Buy |
+2,230
| New | +$10.6K | ﹤0.01% | 2619 |
|
BlackRock's SCLN Position: Q4 2017 in Review
BlackRock sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 7,330,329 shares — an estimated $82.1M sold.
BlackRock first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $82.1M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- BlackRock reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- BlackRock sold 7,330,329 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $82.1M.
- BlackRock first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- BlackRock's Sciclone Pharmaceuticals Inc position peaked at $82.1M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on BlackRock's 13F filing for Q4 2017, filed 9 Feb 2018.